Drug Trial News

RSS

Alnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment of ATTR

Alnylam Pharmaceuticals a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTRsc, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).

19 Mar 2013

Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Oncology, Astellas Pharma US, Inc. Global Development

Tivozanib is an oral, once-daily, investigational tyrosine kinase inhibitor, or TKI, that is being investigated for use in patients with advanced renal cell carcinoma (RCC), or kidney cancer.

19 Mar 2013

University of Nottingham to study use of tranexamic acid in people with intracerebral haemorrhage

Scientists in Nottingham are leading an international study to investigate the effectiveness of a new treatment on a devastating type of stroke.

19 Mar 2013

R-Tech Ueno enrolls retinitis pigmentosa patients in Phase 3 clinical study of UF-021 ophthalmic solution

R-Tech Ueno is pleased to announce the start of the patient enrollment of a Phase 3 clinical study with Unoprostone (development code UF-021) ophthalmic solution that are being developed in our company for the treatment of retinitis pigmentosa.

18 Mar 2013

Abiraterone's anti-androgenic properties may stop tumor growth of CRPC, says prize-winning Dutch study

As part of an EU-supported IMI-PREDECT consortium, a Dutch study showed that anti-androgenic properties of the drug abiraterone may provide an additional mechanism of action in blocking tumour growth of castration resistant prostate cancer (CRPC).

16 Mar 2013

Diffusion Pharmaceuticals enrolls patients with primary brain cancer in Phase II clinical trial of TSC

Diffusion Pharmaceuticals LLC today announced completion of enrollment in a Phase II clinical trial of trans sodium crocetinate, its lead compound for the treatment of cancer.

15 Mar 2013

Results from GTx's Phase 2 clinical trial of enobosarm published online

GTx, Inc. today announced that the journal, The Lancet Oncology, has published online ahead of its April print edition the results from GTx's randomized, double-blind, placebo-controlled Phase 2 clinical trial of enobosarm to assess its effects on muscle wasting and physical function in patients with cancer.

15 Mar 2013

Phase 1b study of olesoxime initiated in multiple sclerosis (MS) patients

...

14 Mar 2013

Steroids used for treating TB may reduce death rates from all types of TB

The routine use of steroids to treat tuberculosis may help reduce deaths from all types of the disease, according to a new review of existing research.

14 Mar 2013

ASTRONAUT trial finds no beneficial effects of aliskiren in recently hospitalized heart failure patients

Despite high hopes that a blood pressure-lowering medication called aliskiren would help people following hospitalization for heart failure, no beneficial effects were found, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

Eplerenone may also reduce risk of heart failure, shows REMINDER trial

The prescription drug eplerenone appears to reduce the risk of cardiovascular mortality and heart failure after a heart attack by more than one-third, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

STREAM trial: Treatment with tenecteplase before hospital transfer benefits some

A clot-busting therapy may benefit some heart attack patients who cannot have immediate angioplasty, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

EDTA chelation, high-dose vitamins/minerals may provide additional benefit for MI patients

Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

Trial evaluates ranolazine in patients with diabetes, coronary artery disease and angina

A commonly used anti-anginal drug reduces chest pain in patients with type 2 diabetes and appears to have a more pronounced effect in those with poorer glucose control, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

RELAX study finds no beneficial effects of erectile dysfunction drug for diastolic heart failure

Despite high expectations for a commonly used erectile dysfunction drug to treat patients with diastolic heart failure, no beneficial effects were found in a study presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

Lithera commences LIPO-202 Phase 2b trial for reduction of subcutaneous fat

Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, announced today that the first patient has been treated with LIPO-202 (Salmeterol Xinafoate for Injection) in its 500-patient Phase 2b "RESET" trial.

12 Mar 2013

Cangrelor solidly outperforms clopidogrel during percutaneous coronary intervention

The experimental anti-clotting drug cangrelor solidly outperformed commonly used clopidogrel in a large global trial of patients who underwent coronary stent procedures, according to data from the phase III CHAMPION PHOENIX study presented today at the American College of Cardiology's 62nd Annual Scientific Session.

12 Mar 2013

Cangrelor more effective than clopidogrel in preventing blood clots

A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures.

12 Mar 2013

High-dose rosuvastatin reduces acute kidney injury caused by imaging dye in ACS patients

High doses of a popular cholesterol-lowering drug significantly reduced the rate of acute kidney injury caused by dye used in imaging in acute coronary syndrome patients who underwent a coronary procedure, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

12 Mar 2013

Aliskiren and standard therapy not associated with reduced CV death or HF rehospitalization

Among patients hospitalized for heart failure (HF) with reduced left ventricular ejection fraction (LVEF; a measure of how well the left ventricle of the heart pumps with each contraction), initiation of the medication aliskiren in addition to standard therapy did not reduce cardiovascular death or HF rehospitalization at 6 or 12 months after discharge, according to a study published online by JAMA.

12 Mar 2013

Drug Trial News

Alnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment of ATTR

Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Oncology, Astellas Pharma US, Inc. Global Development

University of Nottingham to study use of tranexamic acid in people with intracerebral haemorrhage

R-Tech Ueno enrolls retinitis pigmentosa patients in Phase 3 clinical study of UF-021 ophthalmic solution

Abiraterone's anti-androgenic properties may stop tumor growth of CRPC, says prize-winning Dutch study

Diffusion Pharmaceuticals enrolls patients with primary brain cancer in Phase II clinical trial of TSC

Results from GTx's Phase 2 clinical trial of enobosarm published online

Phase 1b study of olesoxime initiated in multiple sclerosis (MS) patients

Steroids used for treating TB may reduce death rates from all types of TB

ASTRONAUT trial finds no beneficial effects of aliskiren in recently hospitalized heart failure patients

Eplerenone may also reduce risk of heart failure, shows REMINDER trial

STREAM trial: Treatment with tenecteplase before hospital transfer benefits some

EDTA chelation, high-dose vitamins/minerals may provide additional benefit for MI patients

Trial evaluates ranolazine in patients with diabetes, coronary artery disease and angina

RELAX study finds no beneficial effects of erectile dysfunction drug for diastolic heart failure

Lithera commences LIPO-202 Phase 2b trial for reduction of subcutaneous fat

Cangrelor solidly outperforms clopidogrel during percutaneous coronary intervention

Cangrelor more effective than clopidogrel in preventing blood clots

High-dose rosuvastatin reduces acute kidney injury caused by imaging dye in ACS patients

Aliskiren and standard therapy not associated with reduced CV death or HF rehospitalization

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News